Literature DB >> 10574370

Inhibition of DNA synthesis in human gliomas by roscovitine.

J S Yakisich1, J Boethius, I O Lindblom, L Wallstedt, V I Vargas, A Sidén, M H Cruz.   

Abstract

The early effect of 1-100 microM roscovitine, a purine analogue and cyclin-dependent kinase inhibitor, was studied on tissue specimens from eight human malignant gliomas. The tissue was incubated immediately after resection with DMEM containing [3H]methylthymidine plus vehicle alone or the proper concentration of roscovitine for 30-90 min. The DNA synthesis rate was assessed by measurement of [3H]methylthymidine incorporation into trichloroacetic acid insoluble material/mg protein/min. In all gliomas, 100 microM roscovitine inhibited DNA synthesis by 71-97% (average 89 +/- 8%, p<0.0001). This inhibitory effect of roscovitine appeared within 30 min of incubation and was concentration dependent.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10574370     DOI: 10.1097/00001756-199908200-00023

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  4 in total

1.  Imatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine.

Authors:  Mine Erguven; Ayhan Bilir; Nuray Yazihan; Seval Korkmaz; Esin Aktas; Cem Ovalioglu; Tolga Dundar; Hakan Seyithanoglu
Journal:  Oncol Lett       Date:  2011-10-04       Impact factor: 2.967

2.  Strong inhibition of replicative DNA synthesis in the developing rat cerebral cortex and glioma cells by roscovitine.

Authors:  Juan Sebastian Yakisich; Marina Fernanda Vita; Ake Siden; Deborah Ruth Tasat; Mabel Cruz
Journal:  Invest New Drugs       Date:  2009-04-24       Impact factor: 3.850

3.  Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells.

Authors:  Mohamed Salah I Abaza; Abdul-Majeed A Bahman; Rajaa J Al-Attiyah
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

Review 4.  Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology?

Authors:  Christin Riess; Nina Irmscher; Inken Salewski; Daniel Strüder; Carl-Friedrich Classen; Christina Große-Thie; Christian Junghanss; Claudia Maletzki
Journal:  Cancer Metastasis Rev       Date:  2020-11-08       Impact factor: 9.264

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.